Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $936 from $928 and keeps a Buy rating on the shares after detailing how the firm is thinking about GLP1 market dynamics through the remainder of the year. Both Lilly and Novo Nordisk (NVO) have stated their strong preference for open access and the firm notes as part of the updated agreement with Express Scripts and Cigna’s (CI) Evernorth announced Wednesday that the companies maintained open access through the end of 2026 for Wegovy and Zepbound with prices “in line with Lilly’s normal price concessions,” per the company. Overall, the firm believes both companies are positioned to meet 2025 guidance, although it continues to assume Novo will be at the low end of guidance with material risk to sales and earnings in 2026-27 if GLP1 prescriptions don’t accelerate.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Evernorth weight loss drug price point attractive compared to Hims, says Truist
- Citi says Evernorth plan ‘slight headwind’ to Hims & Hers
- Cigna’s Evernorth caps monthly weight loss drug cost at $200
- Eli Lilly’s Kisunla granted marketing authorization in Australia for Alzheimer’s
- Senior Executive at Eli Lilly (LLY) Sells Company Stock